João Victor Pereira Gonzalez

João Victor Pereira Gonzalez

Auto-generated profile, based on publicly available information

João Victor Pereira Gonzalez

Bahiana School of Medicine and Public Health, Brotas, Salvador, Bahia, Brazil

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2025 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
LFLuciano Falcão
Luciano Falcão
PGPedro Antonio Lopes Gomes
Pedro Antonio Lopes Gomes
RSRafael Andrade Sampaio Silva
Rafael Andrade Sampaio Silva
KOKenzo Ogasawara
Kenzo Ogasawara
JGJoão Victor Pereira Gonzalez
João Victor Pereira Gonzalez
DSDavi J. Fontoura Solla
Davi J. Fontoura Solla

16 July 2026 in Neurological Sciences
Verified
Journal Article
Open access
PDF file
LLLetícia Guimarães Lopes
Letícia Guimarães Lopes
AOAdriane Santos Oliveira
Adriane Santos Oliveira
CFCamila Carvalho Fingergut
Camila Carvalho Fingergut
GBGabriela Nunes E Brito
Gabriela Nunes E Brito
JGJoão Victor Pereira Gonzalez
João Victor Pereira Gonzalez
CCCristina Salles de Castro
Cristina Salles de Castro
Background: Circadian rhythm dysregulation may contribute to sleep-wake disorders and cognitive impairment. In the elderly, circadian abnormalities have been observed in Mild Cognitive Impairment (MCI), suggesting a possible association between neurocognitive deficits and circadian dysfunctions. Objective: To analyze the association between circadian rhythm disturbances and cognitive decline in the population aged ≥ 60 years. Methods: This systematic review included studies evaluating the association between circadian rhythm disturbances and cognitive decline in elderly individuals aged 60 years or older, with self-reported or objectively measured sleep data and cognitive assessment via questionnaires. Studies tracking progression from MCI to Alzheimer’s disease (AD) were retained, as they capture circadian changes across the MCI-to-dementia continuum. Studies that evaluated other sleep disorders and/or other conditions of cognitive impairment exclusively or that did not specify the mean age of the participants were excluded. Results: Ten studies were included, totaling 5,731 participants (5 , 707 eligible for analysis ). Circadian exposures were organized into three domains: (1) actigraphic rest-activity rhythm metrics (amplitude, robustness, interdaily stability, intradaily variability, and acrophase); (2) sleep quality and architecture parameters (efficiency, fragmentation, latency, WASO, and melatonin timing); and (3) circadian-disrupting lifestyle exposures (rotating night shift work). Across these domains, circadian dysregulation was consistently associated with a higher risk of development or progression of MCI and dementia. Conclusion: Circadian and sleep disturbances negatively impact cognitive health in the elderly, reinforcing the need for further research on this association and its public health implications.

20 August 2026 in Headache: The Journal of Head and Face Pain
Verified
Journal Article
Closed access
PDF file
LFLuciano Falcão
Luciano Falcão
LBLeonardo de Barros Oliveira Brenner
Leonardo de Barros Oliveira Brenner
PMPedro Lucas Machado Magalhães
Pedro Lucas Machado Magalhães
AGAbhishek Goyal
Abhishek Goyal
MMMariana Leticia de Bastos Maximiano
Mariana Leticia de Bastos Maximiano
KZKatherine Zarroli
Katherine Zarroli

22 February 2026 in Neurological Research
Verified
Journal Article
Closed access
IPIago Nathan Simon Petry
Iago Nathan Simon Petry
GTGabriel Caruso Novaes Tudella
Gabriel Caruso Novaes Tudella
MMMariana Letícia de Bastos Maximiano
Mariana Letícia de Bastos Maximiano
YSYasmin Picanco Silva
Yasmin Picanco Silva
JGJoão Victor Pereira Gonzalez
João Victor Pereira Gonzalez
WFWalter Fagundes
Walter Fagundes
Post-stroke fatigue (PSF) is a common and disabling condition that limits rehabilitation and quality of life, yet no pharmacological treatment is well established. Modafinil, a wakefulness-promoting agent, has been proposed as a potential therapy. This systematic review and meta-analysis evaluated its efficacy and safety in PSF. Four studies (two RCTs, two observational) comprising 1001 met inclusion criteria. Modafinil did not significantly improve overall fatigue severity on the MFI or FSS. A domain-specific benefit was observed for mental fatigue (MD -2.51; p = 0.0005), with no significant effects on physical, general, or activity-related fatigue. No improvements were found in quality of life (SSQoL) or cognition (MoCA). Modafinil was generally well tolerated with few mild adverse events. Current evidence does not support modafinil as a routine treatment for PSF. Its effect on mental fatigue is of very low certainty, limiting the strength of this finding. Clinicians should interpret these findings cautiously, and use modafinil only on a case-by-case basis. Larger, high-quality trials with standardized fatigue measures are needed to identify responders and clarify its clinical role.

17 August 2026 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
PDF file
LNLucas Macedo Nascimento
Lucas Macedo Nascimento
CLCaio Toscano Lessa
Caio Toscano Lessa
AVAna Clara Monte Varandas
Ana Clara Monte Varandas
JGJoão Victor Pereira Gonzalez
João Victor Pereira Gonzalez
VRValentina Meinhardt Ronchetti
Valentina Meinhardt Ronchetti
ASAndré Luiz Lopes Sampaio
André Luiz Lopes Sampaio

14 February 2026 in Neurological Research
Verified
Journal Article
Closed access
MMMariana Letícia de Bastos Maximiano
Mariana Letícia de Bastos Maximiano
OGOcílio Ribeiro Gonçalves
Ocílio Ribeiro Gonçalves
LFLuciano Falcão
Luciano Falcão
LCLucca Tamara Alves Carretta
Lucca Tamara Alves Carretta
MHMariana Lee Han
Mariana Lee Han
AGAhmet Günkan
Ahmet Günkan
Wea im to evaluate the impact of Dual Antiplatelet Therapy (DAPT) pretreatment on outcomes in patients with Acute Ischemic Stroke (AIS) undergoing intravenous thrombolysis (IVT). A systematic search was conducted from inception to January 2025. Eligible studies included randomized and observational cohorts comparing AIS patients with and without DAPT pretreatment who underwent IVT. Primary outcome was favorable functional outcome at 90 days (mRS 0-1). Secondary outcomes included mRS 0-2, mRS 3-6, in-hospital and 90-day mortality, and symptomatic intracranial hemorrhage (sICH) defined by SITS-MOST, ECASS II, and NINDS criteria. Risk of bias was assessed using the ROBINS-I tool, and meta-analyses were performed with random-effects models. Eight studies including 296,854 patients (61,925 with DAPT and 234,929 without DAPT) were analyzed. DAPT pretreatment was not associated with favorable functional outcome (mRS 0-1; OR: 1.03; 95% CI: 0.92-1.16; p = 0.57; I2 = 0%), in-hospital mortality (OR: 1.00; 95% CI: 1.00-1.00; I2 = 0%), or 90-day mortality (OR: 1.49; 95% CI: 0.99-2.25; p = 0.06; I2 = 52%). No significant increase in sICH was observed using SITS-MOST (I2 = 64%) or ECASS II (I2 = 63%), whereas sICH defined by NINDS was increased (OR: 1.31; 95% CI: 1.19-1.44; p < 0.01; I2 = 48%), corresponding to a 1% absolute risk increase (RD: 0.01; I2 = 0%). Prestroke DAPT was not associated with favorable functional outcome or reduced mortality after IVT and was associated with a higher risk of sICH when defined by NINDS criteria, with a 1% absolute risk increase.